Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

• Hoofdauteurs: Juthamas Prawjaeng (Auteur), Pattara Leelahavarong (Auteur), Nuttakarn Budtarad (Auteur), Songyot Pilasant (Auteur), Chonticha Chanjam (Auteur), Wanruchada Katchamart (Auteur), Pongthorn Narongroeknawin (Auteur), Tasanee Kitumnuaypong (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2023-05-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background New biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all showed greater clinical benefits in the treatment of patients with rheumatoid arthritis (RA) with high disease activity, but imposed higher cost...